Business Wire

Evotix on Mission to Reduce Workplace Accidents in Europe and USA

2.11.2021 12:00:00 EET | Business Wire | Press release

Share

Every year over 5,000 people are killed in workplace accidents in the US and EU – a number that’s risen in the US over the last ten years1 - and blue-collar workers in the US are five times as likely to have accidents as their white-collar counterparts2.

Evotix, an ESG business, formerly known as SHE Software and a world leader in environmental, health, safety and well-being software (EHS), announces today its mission to help organizations reduce these numbers through its investment in new staff, software, support and training services.

The business’ proposition is focussed on giving its clients ‘the confidence to transform’. For many organizations, changing the way they handle health and safety can be daunting because they don’t want to uproot established practices even if they are based on out-of-date processes and technologies. Evotix has the in-depth expertise in the latest technologies, especially those that improve and simplify the user experience, that enables organizations to implement the changes they – and their employees – need to make EHS simpler and safer.

Matthew Elson, CEO of Evotix, explains, “People, especially those that are less advantaged, have the right to work in a safer environment. Our business already helps protect the safety of over 3,000,000 employees worldwide and we’re determined to protect many, many more in the years to come.”

“Too many employees suffer workplace accidents or endure workplace related physical and mental health problems, causing issues not only for those individuals but for businesses and wider society. Many of these unfortunate situations would be avoidable if health and safety were embedded in the way the organization truly functions, supported by software featuring the latest user-friendly technologies. Engaging employees on safety issues needs to be simple, sustainable and tailored for the need of each individual organization and that’s what Evotix has been built to offer.”

“The introduction of the Evotix name is just one step on our journey. The SHE Software name has served us well during our early years, but we wanted a name that was both memorable and reflects our vision and evolved proposition. The Evotix name is a conflation of the key qualities that make us special – evolutionary technology, innovation and experience.”

Based in Chicago and London, over the past five years Evotix has grown by over 40% every year and now has over 130 staff across the US, Europe and Asia-Pacific. In the last two years the company has experienced its fastest ever growth and major customers include: GlaxoSmithKline, New Balance, Citrix and University of Cambridge.

SOLUTIONS FOR TOMORROW

Evotix focusses on promoting workplace health and safety by providing innovative and engaging technology that gets embedded in the everyday flow of activity.

Evotix provides a comprehensive solution covering all aspects of health and safety management.

The solution is online and mobile-first designed to be used quickly and easily on-the-spot. With Evotix, incidents can be reported and shared within minutes, actions can be tracked to completion and underlying trends can be analysed.

Understanding documents on a mobile phone can be challenging: many organizations have a percentage of their workforce who are illiterate. Evotix employs microlearning video and quizzes in the field to engage employees in understanding risk and following defined working methods.

Every organization is different so the software can be easily tailored and adapted as requirements evolve. Evotix is continually adding new innovation as technology evolves.

Matthew continues, “Our approach helps organizations and employees alike. For organizations, accidents and incidents are expensive, with direct costs including lost hours, damage, disruption and claims, and indirect costs including the impact on morale, reputation, stress and management distraction. “

“We believe employees deserve better. The risks associated with workplace accidents fall disproportionately on the most disadvantaged in society - gig economy workers, casual labourers. An organization that prioritises risk reduction for all its staff will perform better financially, operationally and reputationally. That’s where we are here to help.”

Dawn Hemmings at Citrix says, “I’ve partnered with Evotix for over five years at three different organisations. I have always valued them as a partner that cares as passionately about improving workplace safety as I do. That’s why, when I joined Citrix, one of my first actions was to call Evotix. We know that their vision to make EHS simpler, more intuitive and more engaging is aligned with ours and they have the capabilities and plans to make that vision a reality.”

ABOUT EVOTIX

Evotix is a global ESG technology company transforming the way employees engage in workplace health and safety. Its market leading solution, Assure, is used by more than 400 customers across a wide range of industries including manufacturing, food & drink, construction, utility services, transport & logistics, municipalities, healthcare, education and housing.

Customers include GlaxoSmithKline, New Balance, Citrix, Finsbury Foods, Eddie Stobart, Network Rail, Wacker Neuson, Euro Car Parts and University of Cambridge.

Evotix’s intuitive, mobile first application fosters worker participation, guiding frontline activities while capturing rich data to help prioritise safety and operational improvements and ensure compliance. Ease of deployment and resulting swift customer impact drive Evotix’s rapid multi-year growth.

Evotix has offices in Chicago, London, Manchester, Glasgow and Melbourne, and is backed by significant investors including Mercia Asset Management and Frog Capital.


1 Eurostat: Accidents at work; US Bureau of Labor Statistics: Fatal occupational injuries
2 US Bureau of Labor Statistics: Fatal occupational injuries

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Giles Fraser at Brands2Life
+44 207 592 1200
info@brands2life.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release

Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye